Compare MGM Resorts International (MGM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Sanofi SA — how do they compare? MGM Resorts International trades at $29.3 (market cap $7.55B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 12.6× MGM Resorts International's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Sanofi SA for 94 Days on average.
| MGM | SNY | |
|---|---|---|
Market Cap | $7.55B | $95.18B |
Volume | 5,342,346 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $52.34 |
52-Week Low | $30.00 | $39.51 |
Typical Hold Time | 91 Days | 94 Days |
Enterprise Value | $34.85B | $114.48B |
Dividend Yield | 0.03% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) stock is trading at $29.27, down 2.43% on the day and reflecting significant pressure following the collapse of Barry Diller's $48.30 per share acquisition proposal in late September 2026. The technical picture is bearish, while fundamentals show mixed signals with revenue growth to $17.54B in 2025 but declining net income margins. Analyst sentiment remains predominantly positive with a consensus price target of $48.75, suggesting substantial upside potential from current levels.
The investment case hinges on MGM's ability to execute its strategic initiatives and potentially pursue acquisitions like People Inc. to unlock value. Near-term risks include integration challenges, market volatility, and execution missteps. The current valuation at a P/E of 18.19 and P/S of 0.45 appears reasonable if management can stabilize profitability and navigate the post-deal uncertainty.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
